



FILE COPY

Receipt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Provisional Application of

POMPEJUS et al.

Serial No. 09/582,779

Filed: July 3, 2000

For: OROTIDINE-5'PHOSPHATE DECARBOXYLASE-GENE, GENE CONSTRUCT
CONTAINING SAID GENE AND THE UTILIZATION THEREOF

Application Processing
Division
Customer Correction Branch

I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in
an envelope addressed to Commissioner of Patents and
Trademarks, Washington, D.C. 20231, on:

December 27, 2000

Date of Deposit

Monica K. Sims

Person Making Deposit

Signature

December 27, 2000

Date of Signature

REQUEST FOR CORRECTED FILING RECEIPT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

RECEIVED
MAR 19 2001
TECH CENTER 1600/2900

Sir:

Please forward a corrected filing receipt as follows:

Applicants are not eligible for Small Entity Status. Please remove this
information from the filing receipt.

The error is the fault of the Patent Office, no fee is required.


Respectfully submitted,

KEIL & WEINKAUF

H B Keil

Herbert B. Keil
Reg. No. 18,967

1101 Connecticut Avenue, N.W.
Washington, D.C. 20036
(202) 659-0100
HBK/mks



UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/582,779	07/03/2000	1632	840	48715	1	15	2

 KEIL & WEINKAUF
 1101 CONNECTICUT AVENUE NW
 WASHINGTON, DC 20036

CORRECTED FILING RECEIPT



OC000000005587472

Date Mailed: 11/30/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

 MARKUS POMPEJUS, WALDSEE, GERMANY;
 JOSE LUIS REVUELTRA DOVAL, SALAMANCA, SPAIN;
 MARIA ANGELES SANTOS GARCIA, SALAMANCO, SPAIN;

RECEIVED

MAR 19 2001

TECH CENTER 1600/2900

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A 371 OF PCT/EP98/08382 01/15/1998

Foreign Applications

GERMANY 19801120.2 01/15/1998

If Required, Foreign Filing License Granted 08/17/2000

** SMALL ENTITY **

Title

 OROTIDINE-5'-PHOSPHATE DECARBOXYLASE-GENE, GENE CONSTRUCT
 CONTAINING SAID GENE AND THE UTILIZATION THEREOF

Preliminary Class

435



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

FILE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



Bib Data Sheet

SERIAL NUMBER 09/582,779	FILING DATE 07/03/2000 RULE -	CLASS 435	GROUP ART UNIT 1632	ATTORNEY DOCKET NO. 48715
------------------------------------	---	---------------------	-------------------------------	-------------------------------------

APPLICANTS
MARKUS POMPEJUS, WALDSEE, GERMANY;
JOSE LUIS REVUELTRA DOVAL, SALAMANCA, SPAIN;
MARIA ANGELES SANTOS GARCIA, SALAMANCO, SPAIN;

**** CONTINUING DATA ******* 12/18/1998
THIS APPLICATION IS A 371 OF PCT/EP98/08382-01/15/1998-
12

**** FOREIGN APPLICATIONS *******
GERMANY 19801120.2 01/15/1998
12

IF REQUIRED, FOREIGN FILING LICENSE
GRANTED ** 08/17/2000

Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY GERMANY	SHEETS DRAWING 1	TOTAL CLAIMS 15	INDEPENDENT CLAIMS 2
35 USC 119 (a-d) conditions met <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged 240 Examiner's Signature	Initials 12			

ADDRESS
KEIL & WEINKAUF
1101 CONNECTICUT AVENUE NW
WASHINGTON, DC 20036

TITLE
OROTIDINE-5'-PHOSPHATE DECARBOXYLASE-GENE, GENE CONSTRUCT CONTAINING SAID GENE AND THE UTILIZATION THEREOF

FILING FEE RECEIVED 840	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit